Jeffrey M Jacobson

Summary

Affiliation: Drexel University College of Medicine
Country: USA

Publications

  1. doi request reprint Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19104, USA
    J Infect Dis 198:1345-52. 2008
  2. pmc Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Antimicrob Agents Chemother 53:450-7. 2009
  3. pmc Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Infect Dis 201:1481-7. 2010
  4. pmc Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
    Antimicrob Agents Chemother 54:4137-42. 2010
  5. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010
  6. doi request reprint Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial
    Noah McKittrick
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Intern Med 158:19-26. 2013
  7. pmc Combinatorial approaches to the prevention and treatment of HIV-1 infection
    Vanessa Pirrone
    Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, New College Building, Philadelphia PA 19102, USA
    Antimicrob Agents Chemother 55:1831-42. 2011
  8. pmc Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial
    Benigno Rodriguez
    Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University University Hospitals of Cleveland, Cleveland, OH Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA University of Pittsburgh, Pittsburgh, PA Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD Department of Medicine, Rush University Medical Center, Chicago, IL ViroStatics srl, Sassari, Italy Genetic Immunity, Budapest, Hungary Genetic Immunity, McLean, VA and Social and Scientific Systems, Inc, Silver Spring, MD
    J Acquir Immune Defic Syndr 64:351-9. 2013
  9. pmc Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
    Livio Azzoni
    1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
    J Infect Dis 207:213-22. 2013
  10. ncbi request reprint Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Zahida Parveen
    Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Curr HIV Res 5:281-92. 2007

Research Grants

  1. Long-Acting HIV Therapy for Injection Drug Users
    Jeffrey M Jacobson; Fiscal Year: 2010

Collaborators

Detail Information

Publications12

  1. doi request reprint Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19104, USA
    J Infect Dis 198:1345-52. 2008
    ..The chemokine receptor CCR5 provides an entry portal for HIV-1, and PRO 140 is a humanized monoclonal antibody that binds to CCR5 and potently inhibits CCR5-tropic (R5) HIV-1 in vitro...
  2. pmc Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults
    Jeffrey M Jacobson
    Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Antimicrob Agents Chemother 53:450-7. 2009
    ..In conclusion, ibalizumab administered either weekly or biweekly was safe and well tolerated and demonstrated antiviral activity. Further studies with ibalizumab in combination with standard antiretroviral treatments are warranted...
  3. pmc Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvania 19104, USA
    J Infect Dis 201:1481-7. 2010
    ..This study is the first to evaluate subcutaneous administration...
  4. pmc Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults
    Jeffrey M Jacobson
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, 245 N 15th St, MS 461, Philadelphia, PA 19104, USA
    Antimicrob Agents Chemother 54:4137-42. 2010
    ..The findings further delineate the safety and antiviral properties of this novel, long-acting antiretroviral agent...
  5. doi request reprint Ibalizumab: an anti-CD4 monoclonal antibody for the treatment of HIV-1 infection
    Christopher J Bruno
    Division of Infectious Diseases and HIV Medicine, Department of Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    J Antimicrob Chemother 65:1839-41. 2010
    ..Its unique mode of action reduces the risk of cross-resistance with currently available antiretroviral agents, with the potential to expand the choices available to treat drug-resistant HIV-1...
  6. doi request reprint Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial
    Noah McKittrick
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Intern Med 158:19-26. 2013
    ..HIV-infected persons have less robust antibody responses to influenza vaccines...
  7. pmc Combinatorial approaches to the prevention and treatment of HIV-1 infection
    Vanessa Pirrone
    Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, New College Building, Philadelphia PA 19102, USA
    Antimicrob Agents Chemother 55:1831-42. 2011
    ..The shift in focus within the microbicide development field from single compounds to combination approaches is also explored...
  8. pmc Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial
    Benigno Rodriguez
    Division of Infectious Diseases and Center for AIDS Research, Case Western Reserve University University Hospitals of Cleveland, Cleveland, OH Division of Infectious Diseases, University of California Davis Medical Center, Sacramento, CA Statistical and Data Analysis Center, Harvard School of Public Health, Boston, MA Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA University of Pittsburgh, Pittsburgh, PA Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD Department of Medicine, Rush University Medical Center, Chicago, IL ViroStatics srl, Sassari, Italy Genetic Immunity, Budapest, Hungary Genetic Immunity, McLean, VA and Social and Scientific Systems, Inc, Silver Spring, MD
    J Acquir Immune Defic Syndr 64:351-9. 2013
    ..DermaVir, a topically administered plasmid DNA-nanomedicine expressing HIV (CladeB) virus-like particles consisting of 15 antigens, induces predominantly central memory T-cell responses...
  9. pmc Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration
    Livio Azzoni
    1HIV 1 Immunopathogenesis Laboratory, The Wistar Institute, Philadelphia, PA, USA
    J Infect Dis 207:213-22. 2013
    ..Antiretroviral therapy (ART)-mediated immune reconstitution fails to restore the capacity of the immune system to spontaneously control human immunodeficiency virus (HIV) replication...
  10. ncbi request reprint Effects of highly active antiretroviral therapy on HIV-1-associated oral complications
    Zahida Parveen
    Division of Infectious Diseases, Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA
    Curr HIV Res 5:281-92. 2007
    ..Future directions envisioned by the National Institutes of Health as well as novel avenues to be explored are also presented...
  11. pmc Body mass index and CD4+ T-lymphocyte recovery in HIV-infected men with viral suppression on antiretroviral therapy
    Brandon Palermo
    Division of Infectious Diseases and HIV Medicine, Drexel University College of Medicine, Philadelphia, PA, USA
    HIV Clin Trials 12:222-7. 2011
    ..To better characterize the relationship between body mass index (BMI) and CD4+ T-lymphocyte recovery in HIV disease...
  12. pmc Development of co-selected single nucleotide polymorphisms in the viral promoter precedes the onset of human immunodeficiency virus type 1-associated neurocognitive impairment
    Luna Li
    Department of Microbiology and Immunology, Drexel University College of Medicine, 245 N 15th Street, MS 1013A, Philadelphia, PA 19102, USA
    J Neurovirol 17:92-109. 2011
    ....

Research Grants1

  1. Long-Acting HIV Therapy for Injection Drug Users
    Jeffrey M Jacobson; Fiscal Year: 2010
    ..We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. ..